Erschienen in:
14.11.2018 | Original Article
Role of the HDAC6/STAT3 pathway in regulating PD-L1 expression in osteosarcoma cell lines
verfasst von:
Ajimu Keremu, Abudusaimi Aimaiti, Zhilin Liang, Xiaoguang Zou
Erschienen in:
Cancer Chemotherapy and Pharmacology
|
Ausgabe 2/2019
Einloggen, um Zugang zu erhalten
Abstract
Histone deacetylases (HDACs), initially described as histone modifiers, have more recently been verified to target various other proteins unrelated to the chromatin environment. On this basis, findings of the current study demonstrates that the pharmacological or genetic abrogation of HDAC6 in osteosarcoma cell lines down-regulates the expression of program death receptor ligand-1 (PD-L1), an important co-stimulatory molecule expressed in cancer cells, which activates the inhibitory regulatory pathway PD-1 in T cells. As shown by our results, the mechanism by which HDAC6 regulated PD-L1 expression was mediated by the transcription factor STAT3. In addition, we observed that selective HDAC6 inhibitors could inhibit tumor progression in vivo. Crucially, these results provide an essential pre-clinical rationale and justification for the necessity of further research on HDAC6 inhibitors as potential immuno-modulatory agents in osteosarcoma.